Asieris Reports the Completion of First Patient Dosing of Hexvix for the Treatment of Bladder Cancer
Shots:
- The company has completed the first patient dosing in the P-III bridging trial to evaluate the additional detection rate and safety of Hexvix and BLC vs white light cystoscopy in patients with NMIBC
- The study will be led by Peking Union Medical College Hospital and the Chinese Academy of Medical Sciences. Additionally, the company is planning to file an NDA with the NMPA in the future pending clinical trial progress
- In Jan 2021, Asieris & Photocure collaborated to obtain the exclusive registration and commercialization rights of Hexvix in mainland China and Taiwan. Hexvix received approval from the NMPA for P-III clinical trials in Q1’22
Ref: PRNewswire | Image: Asieris
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
